Cibus (CBUS) Competitors

Cibus logo
$1.37 -0.02 (-1.44%)
Closing price 04:00 PM Eastern
Extended Trading
$1.33 -0.04 (-3.14%)
As of 06:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CBUS vs. EDIT, ALT, EIKN, PROK, and LRMR

Should you buy Cibus stock or one of its competitors? Cibus's main competitors and comparable companies include Editas Medicine (EDIT), Altimmune (ALT), Eikon Therapeutics (EIKN), ProKidney (PROK), and Larimar Therapeutics (LRMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cibus compare to Editas Medicine?

Cibus (NASDAQ:CBUS) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

33.8% of Cibus shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 29.9% of Cibus shares are owned by company insiders. Comparatively, 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Cibus had 7 more articles in the media than Editas Medicine. MarketBeat recorded 18 mentions for Cibus and 11 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.34 beat Cibus' score of -0.31 indicating that Editas Medicine is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cibus
2 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Editas Medicine
4 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cibus has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market.

Cibus has higher earnings, but lower revenue than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cibus$3.64M29.27-$127.08M-$1.50N/A
Editas Medicine$40.52M6.97-$160.06M-$0.62N/A

Editas Medicine has a net margin of -144.95% compared to Cibus' net margin of -2,131.38%. Editas Medicine's return on equity of -130.43% beat Cibus' return on equity.

Company Net Margins Return on Equity Return on Assets
Cibus-2,131.38% -526.66% -28.12%
Editas Medicine -144.95%-130.43%-36.45%

Cibus presently has a consensus target price of $9.00, suggesting a potential upside of 547.48%. Editas Medicine has a consensus target price of $5.83, suggesting a potential upside of 218.76%. Given Cibus' higher probable upside, research analysts plainly believe Cibus is more favorable than Editas Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cibus
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Editas Medicine
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

Summary

Editas Medicine beats Cibus on 9 of the 15 factors compared between the two stocks.

How does Cibus compare to Altimmune?

Cibus (NASDAQ:CBUS) and Altimmune (NASDAQ:ALT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Cibus has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market.

Altimmune has a net margin of 0.00% compared to Cibus' net margin of -2,131.38%. Altimmune's return on equity of -29.26% beat Cibus' return on equity.

Company Net Margins Return on Equity Return on Assets
Cibus-2,131.38% -526.66% -28.12%
Altimmune N/A -29.26%-25.48%

Altimmune has lower revenue, but higher earnings than Cibus. Altimmune is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cibus$3.64M29.27-$127.08M-$1.50N/A
Altimmune$40K7,443.07-$88.09M-$0.72N/A

Cibus presently has a consensus price target of $9.00, indicating a potential upside of 547.48%. Altimmune has a consensus price target of $14.33, indicating a potential upside of 836.82%. Given Altimmune's stronger consensus rating and higher probable upside, analysts plainly believe Altimmune is more favorable than Cibus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cibus
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Altimmune
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70

33.8% of Cibus shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 29.9% of Cibus shares are held by company insiders. Comparatively, 1.6% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Altimmune had 7 more articles in the media than Cibus. MarketBeat recorded 25 mentions for Altimmune and 18 mentions for Cibus. Altimmune's average media sentiment score of 0.50 beat Cibus' score of -0.31 indicating that Altimmune is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cibus
2 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Altimmune
7 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Altimmune beats Cibus on 12 of the 15 factors compared between the two stocks.

How does Cibus compare to Eikon Therapeutics?

Cibus (NASDAQ:CBUS) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

In the previous week, Cibus had 1 more articles in the media than Eikon Therapeutics. MarketBeat recorded 18 mentions for Cibus and 17 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 0.64 beat Cibus' score of -0.31 indicating that Eikon Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cibus
2 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Eikon Therapeutics
3 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

Cibus currently has a consensus target price of $9.00, suggesting a potential upside of 547.48%. Eikon Therapeutics has a consensus target price of $24.67, suggesting a potential upside of 378.96%. Given Cibus' higher possible upside, analysts clearly believe Cibus is more favorable than Eikon Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cibus
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Eikon Therapeutics
2 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.56

Eikon Therapeutics has a net margin of 0.00% compared to Cibus' net margin of -2,131.38%. Eikon Therapeutics' return on equity of -258.13% beat Cibus' return on equity.

Company Net Margins Return on Equity Return on Assets
Cibus-2,131.38% -526.66% -28.12%
Eikon Therapeutics N/A -258.13%-46.00%

Cibus has higher revenue and earnings than Eikon Therapeutics. Eikon Therapeutics is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cibus$3.64M29.27-$127.08M-$1.50N/A
Eikon TherapeuticsN/AN/A-$324.25M-$4.09N/A

33.8% of Cibus shares are owned by institutional investors. 29.9% of Cibus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Cibus beats Eikon Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cibus compare to ProKidney?

Cibus (NASDAQ:CBUS) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Cibus has a net margin of -2,131.38% compared to ProKidney's net margin of -13,326.71%. ProKidney's return on equity of 0.00% beat Cibus' return on equity.

Company Net Margins Return on Equity Return on Assets
Cibus-2,131.38% -526.66% -28.12%
ProKidney -13,326.71%N/A -37.98%

ProKidney has lower revenue, but higher earnings than Cibus. ProKidney is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cibus$3.64M29.27-$127.08M-$1.50N/A
ProKidney$890K373.65-$68.99M-$0.60N/A

Cibus has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market.

Cibus presently has a consensus price target of $9.00, suggesting a potential upside of 547.48%. ProKidney has a consensus price target of $10.00, suggesting a potential upside of 809.09%. Given ProKidney's stronger consensus rating and higher possible upside, analysts clearly believe ProKidney is more favorable than Cibus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cibus
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
ProKidney
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75

33.8% of Cibus shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 29.9% of Cibus shares are held by insiders. Comparatively, 39.8% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Cibus had 3 more articles in the media than ProKidney. MarketBeat recorded 18 mentions for Cibus and 15 mentions for ProKidney. Cibus' average media sentiment score of -0.31 beat ProKidney's score of -0.36 indicating that Cibus is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cibus
2 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
ProKidney
2 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

ProKidney beats Cibus on 11 of the 16 factors compared between the two stocks.

How does Cibus compare to Larimar Therapeutics?

Cibus (NASDAQ:CBUS) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Cibus presently has a consensus target price of $9.00, suggesting a potential upside of 547.48%. Larimar Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 234.45%. Given Cibus' higher probable upside, analysts clearly believe Cibus is more favorable than Larimar Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cibus
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Larimar Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.00

Larimar Therapeutics has a net margin of 0.00% compared to Cibus' net margin of -2,131.38%. Larimar Therapeutics' return on equity of -128.77% beat Cibus' return on equity.

Company Net Margins Return on Equity Return on Assets
Cibus-2,131.38% -526.66% -28.12%
Larimar Therapeutics N/A -128.77%-90.08%

33.8% of Cibus shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 29.9% of Cibus shares are held by company insiders. Comparatively, 4.0% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cibus has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

Cibus has higher revenue and earnings than Larimar Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cibus$3.64M29.27-$127.08M-$1.50N/A
Larimar TherapeuticsN/AN/A-$165.67M-$1.95N/A

In the previous week, Larimar Therapeutics had 9 more articles in the media than Cibus. MarketBeat recorded 27 mentions for Larimar Therapeutics and 18 mentions for Cibus. Larimar Therapeutics' average media sentiment score of 1.09 beat Cibus' score of -0.31 indicating that Larimar Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cibus
2 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Larimar Therapeutics
11 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Larimar Therapeutics beats Cibus on 8 of the 15 factors compared between the two stocks.

Get Cibus News Delivered to You Automatically

Sign up to receive the latest news and ratings for CBUS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CBUS vs. The Competition

MetricCibusBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$105.00M$3.97B$7.60B$11.72B
Dividend YieldN/A3.63%2.47%4.48%
P/E Ratio-0.9124.6233.5830.13
Price / Sales23.1715.438.255.59
Price / CashN/A22.9521.0121.90
Price / Book-19.574.164.443.72
Net Income-$127.08M-$24.10M$3.50B$393.88M
7 Day Performance18.10%-8.44%-6.53%-6.07%
1 Month Performance3.79%-6.54%-4.93%-7.38%
1 Year Performance5.38%-6.71%-1.73%-7.48%

Cibus Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CBUS
Cibus
1.5692 of 5 stars
$1.37
-1.4%
$9.00
+556.9%
+19.8%$105.00M$4.53MN/A118
EDIT
Editas Medicine
2.1764 of 5 stars
$2.17
+1.2%
$5.83
+169.4%
-29.1%$334.15M$40.52MN/A87
ALT
Altimmune
3.9632 of 5 stars
$1.66
+2.8%
$14.33
+766.1%
-63.5%$321.93M$40KN/A57
EIKN
Eikon Therapeutics
3.8174 of 5 stars
$5.95
-1.6%
$24.67
+314.9%
N/A$321.01MN/AN/A384
PROK
ProKidney
1.8469 of 5 stars
$1.05
-9.1%
$10.00
+856.9%
-51.1%$315.92M$890KN/A231

Related Companies and Tools


This page (NASDAQ:CBUS) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners